TrialInfectious disorders drug targets2025

A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022): Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.

Veronika E Izosimova et al.PubMed ↗Publisher ↗

No numbers read from the abstract.